MGC Pharmaceuticals Reaches 800 Patients in Australia and UK

MGC Pharmaceuticals, a cannabinoid medicines maker, has passed 800 patients with prescriptions of its products in Australia and the UK.

MGC Pharmaceuticals (ASX:MXC), a cannabinoid medicines maker, announced it has passed 800 patients with prescriptions of its products in Australia and the United Kingdom (UK).

As quoted in the press release:

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “This material increase in uptake of prescriptions in such short period of time demonstrates the real patient interest and demand for MGC Pharma’s EUGMP grade phytocannabinoid derived products and cost competitiveness of our medicines in our first 2 markets to be accessed. The increased momentum of new prescribed products in Australia and the UK is yet again a testament to the quality and effectiveness of our phytocannabinoid medicines and growing recognition from, and use by, the medical community and we expect to continue to see this growth in new prescriptions

Further Information

MGC Pharma is pleased to have passed a further key milestone as an emerging bio-pharma company during October, with prescriptions for its phytocannabinoid derived medicines reaching over 800 across Australia and the UK demonstrating its strengthening position in each market. Based on recent prescribed product figures, the Company is on track to exceed 1,000 prescriptions during November 2019. In addition, a number of other patients are being treated with MGC Pharma products globally via participation in ongoing clinical research. The commercialisation of its portfolio of phytocannabinoid derived medicines is in line with its strategy of becoming a world-leading bio-pharma company through international distribution agreements.

Click here to read the full press release.

Rio Tinto reaches agreement with Turquoise Hill Resources on financing plan for Oyu Tolgoi

Rio Tinto has entered into a binding Heads of Agreement (HoA) with Turquoise Hill Resources (TRQ) for an updated funding plan (the “Funding Plan”) for the completion of the Oyu Tolgoi (OT) Underground Project in Mongolia. The Funding Plan addresses the estimated remaining known funding requirement of approximately $2.3 billion 1 , building on and replacing the arrangements established in the Memorandum of Understanding that Rio Tinto and TRQ previously entered into on 9 September, 2020.

Under the HoA, subject to securing approval by OT LLC and any required support from the Government of Mongolia, and subject to timing, availability, and terms and conditions being acceptable to both parties, Rio Tinto and TRQ will:

Keep reading... Show less

Rio Tinto Exploration and Calibre Mining Initiate 2021 Exploration Program Including 5,500 Metre Drilling Campaign Prioritizing Prospective Near-Surface Copper and Copper-Gold Mineralization

Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (the “Company” or “Calibre”) is pleased to provide an update on the Borosi exploration project held under an earn-in option agreement between Rio Tinto Exploration (LSE:RIO) (“RTX”) (“Rio Tinto”) and Calibre. Calibre controls a 100% interest in the Borosi concessions located in the prolific Mining Triangle region of northeastern Nicaragua. RTX has the right to earn a 75% interest by spending US$45 million over eleven years in the project ( see Calibre news release dated February 24, 2020 ). The Borosi exploration program is being directed by RTX through a partnership agreement with Calibre as project operator.


Keep reading... Show less

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study –

– Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis

Keep reading... Show less

Rio Tinto details $47 billion 2020 economic contribution, including $8.4 billion of taxes and royalties

Rio Tinto today released its 2020 Taxes paid: Our economic contribution report , which shows the company made a total direct economic contribution of $47 billion in the countries and communities where it operates, including $8.4 billion of taxes and royalties.

Despite the widespread challenges of COVID-19 in 2020, the contribution was up from the previous year, when Rio Tinto made a total direct economic contribution of $45.1 billion in the countries and communities where it operates, including $7.6 billion of taxes and royalties.

Keep reading... Show less

Top News

Related News